Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADH1A | P07327 | 2/20 | 0.45 |
| ▸ | ADH1C | P00326 | 1/20 | 0.45 |
| ▸ | DRD3 | P35462 | 7/20 | 0.42 |
| ▸ | DRD2 | P14416 | 5/20 | 0.42 |
| ▸ | HTR1A | P08908 | 2/20 | 0.42 |
| ▸ | DRD4 | P21917 | 3/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12663274 | 0.98 | DRD3 (0.43) | ADH1AADH1CDRD3DRD2HTR1A | |
| SCHEMBL517191 | 0.95 | ADH1A (0.43) | ADH1AADH1CDRD3DRD2HTR1A | |
| SCHEMBL15508594 | 0.93 | DRD3 (0.44) | ADH1AADH1CDRD3DRD2DRD4 | |
| SCHEMBL627799 | 0.93 | ADH1A (0.45) | ADH1AADH1CDRD3DRD2HTR1A | |
| SCHEMBL24438350 | 0.91 | DRD3 (0.46) | ADH1AADH1CDRD3DRD2DRD4 | |
| Fluoride SCHEMBL9620624 | 0.91 | ADH1A (0.44) | ADH1AADH1CDRD3DRD2HTR1A | |
| Bromide SCHEMBL28388955 | 0.91 | ADH1A (0.44) | ADH1AADH1CDRD3DRD2HTR1A | |
| SCHEMBL3374356 | 0.91 | DRD3 (0.44) | ADH1AADH1CDRD3DRD2HTR1A | |
| SCHEMBL516016 | 0.91 | ADH1A (0.52) | ADH1AADH1CDRD3DRD2HTR1A | |
| SCHEMBL10659147 | 0.90 | DRD3 (0.45) | ADH1AADH1CDRD3DRD2DRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100324091-A1 | Pyrazolone Derivative | KOWA COMPANY, LTD. (JP) | 2010-12-23 | — | — | US | disclosed |
| EP-2172458-A1 | PYRAZOLONE DERIVATIVE | Kowa Company, Ltd. (JP) | 2010-04-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100324091-A1 | Pyrazolone Derivative | SERPINE1, SERPINC1, TFPI | ADH1A 412/4885ADH1C 511/4885DRD3 2098/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.